Korea's Chemizon Inks Drug Development Deal with China's Shenogen Pharma
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean Optomagic subsidiary Chemizon signed a drug development cooperation agreement with China's Shenogen Pharma Group for small molecule therapeutics targeting modulators of the estrogen receptor alpha 36